LONDON (Reuters) – The world’s biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense.
Even as talks fell apart last month, some in Pfizer’s camp remained optimistic the transaction could be revived – and certain AstraZeneca advisers have not ruled out renewed talks. Under British takeover law, the UK firm can approach Pfizer at the end of August to discuss a sweetened bid, or Pfizer can try again in November.
LONDON, June 12 (Reuters) – AstraZeneca has struck a
deal worth up to $232 million in milestone payments to acquire
rights to a drug from Synairgen for treating
respiratory tract viral infections in patients with severe
Britain’s second-biggest drugmaker – subject of a $118
billion bid by Pfizer that failed last month – said on
Thursday it would pay UK-based Synairgen a $7.25 million upfront
fee and potential development, regulatory and commercial
milestones of up to $225 million for rights to the drug,
LONDON, June 2 (Reuters) – Europe’s new one-stop patent
system is winning over companies despite initial criticism from
lawyers and some multinationals of the scheme, which is expected
to come into effect in 2016, according to a survey on Monday.
The Europe-wide unitary patent system offers a cheaper,
simpler solution for businesses seeking to protect their
inventions, rather than having to register and enforce patents
separately in individual European Union countries.
LONDON (Reuters) – GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter.
The move is part of a reshaping of the drugmaker’s business, which also involves a major asset swap deal struck last month with Novartis.